Weight loss drugs are getting more popular, even for teenagers and pre-teens -- but while many doctors have reported ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Interest in weight-loss products continues to surge as calls come for a faster rollout of treatments on the NHS. Research by ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Drugs made to treat diabetes and weight loss could stop or even reverse a severe liver disease, according to a new study. The ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.